hotspot -WSS

hotspot

author：focus 2025-10-01 07:16:52 - browse：5

A sign of Gilead Sciences sits in front of its headquarter and next to a pedestrian crossing sign — health coverage from STAT — Justin Sullivan/Getty Images

The assault on the development of new lifesaving therapies continues apace. Recently, the First Appellate Division of California Appeals held that companies not only have to defend products they have developed and marketed, but also those they have not.

In 2001, Gilead secured FDA approval of tenofovir disoproxil fumarate (TDF), one of first medicines to treat HIV — a product still on the market, despite the potential side effect of causing skeletal and kidney damage. In the years that followed, the company invested in research leading to additional TDF-based regimens critical to the fight against HIV. It had also done preliminary work on a similar but different drug — tenofovir alafenamide fumarate (TAF) — for which it had early, although not definitive, evidence for safety and efficacy.

Ultimately, this medicine was shown to have a better side effect profile than TDF. Starting in 2018, plaintiffs began suing Gilead for negligently failing to develop TAF earlier, on the theory that it wanted to protect the profits from TDF. Now, the California court has agreed to let the suit proceed.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： ALS groups 'won't be played again' by the FDA, drug sponsors

WSS

AstraZeneca loses challenge to Medicare drug price negotiation

Scientists unlock the key to scar

Immune cells and nerve overgrowth may explain recurring UTI pain

Families look for replacement for GSK asthma drug Flovent

Clinical trials giant ICON acquires HumanFirst

Stem cell biologist probes earliest stages of human development

explore

hotspot

knowledge

Heart attack and stroke risk calculators need revising

ALS groups 'won't be played again' by the FDA, drug sponsors

What does generative AI mean for health care? We asked experts

Kale crackers and hibiscus tea: My five days on a 'fasting diet'

As demand for Covid shots wanes, Moderna seeks its next success

Flu vaccine offering decent levels of protection this winter, new data show

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Kale crackers and hibiscus tea: My five days on a 'fasting diet'

Medical leaders decry Supreme Court decision on affirmative action

Ancient Greek ideas underpin modern concepts of pregnancy

leisure time

Pregnant women don't need prenatal multivitamins, study concludes

A new approach to psychiatric drug development

A new approach to psychiatric drug development

Readout Newsletter: BridgeBio, Akero, and human embryo models

Kenai launches with $82 million for Parkinson’s stem cell therapy

Why getting cancer drugs just got harder for rural patients

explore

explore

focus

focus